polyendocrine metabolic ovarian syndrome, new name for polycystic ovarian syndrome . make a ppt from standard articles and journals .(lancet)
Reading File
Reading File
Reading File
Searching PubMed
polycystic ovary syndrome "polyendocrine metabolic" new nomenclature
Searching PubMed
polycystic ovary syndrome PCOS Lancet review 2024 2025
Finding Sources
Searching PubMed
polycystic ovary syndrome PCOS review pathophysiology treatment
Searching the Web
PCOS "polyendocrine metabolic ovarian syndrome" new name Lancet 2024 2025
Reading File
Reading File
Reading Article
Reading Article
Finding Sources
Searching Images
polycystic ovary syndrome PCOS pathophysiology diagram
Reading File
Searching PubMed
PCOS renaming terminology endocrine metabolic ovarian syndrome
Searching the Web
PCOS renamed "polyendocrine metabolic ovarian syndrome" 2024 2025 proposal
Reading File
Finding Sources
Running Command
Writing File
Running Command
Editing File
Running Command
The presentation is ready — 305 KB, 10 slides, clean build.
✅ Presentation Ready
PEMOS PCOS Presentation
Presentation · PPTX
📋 Slide Deck Overview (10 slides)
| # | Slide Title |
|---|---|
| 1 | Title Slide — PEMOS: The New Identity of PCOS |
| 2 | Why the Name Is Changing — Problems with "PCOS" + PEMOS rationale + historical milestones (1935→2025) |
| 3 | Epidemiology & Global Burden — Stats (5–18% prevalence, ×4 T2DM risk), reproductive/metabolic/psychological domains |
| 4 | Pathophysiology — Central node diagram: HPG axis, androgen excess, insulin resistance, adipose dysfunction, genetics, neuroendocrine |
| 5 | Diagnostic Criteria — Rotterdam 2003, 4 phenotypes table, adolescent criteria, exclusion of mimics |
| 6 | Clinical Features Across the Lifespan — Reproductive, metabolic, endocrine/hormonal, psychological, long-term risk |
| 7 | Investigations & Biomarkers — Hormonal panel, metabolic screen, imaging, clinical notes |
| 8 | Evidence-Based Management — 4 pillars: Lifestyle, Metabolic, Reproductive/fertility, Psychological & long-term |
| 9 | Emerging Research & Future Directions — Novel biomarkers, GLP-1/SGLT2, personalised medicine, the PEMOS renaming consensus |
| 10 | References — 7 key citations (Lancet Diabetes Endocrinol 2022, Nat Rev Dis Primers 2024, Harrison's 22e, Berek & Novak's, Goldman-Cecil, JCEM 2023, Fertil Steril 2025) |
Design
- Deep navy background with sapphire blue + rose accent palette
- Card-based layout with colour-coded domains
- All content evidence-sourced from the Lancet Diabetes & Endocrinology (Joham et al. 2022, PMID 35934017), Nature Reviews Disease Primers (Stener-Victorin et al. 2024, PMID 38637590), Harrison's 22e, Berek & Novak's Gynecology, and Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.